[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

Date publication

février 2020

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr VERNEREY Dewi

Tous les auteurs :
Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32057467

Résumé

Perioperative chemotherapy is the standard strategy for localized gastric cancers. Nevertheless, this strategy seems to be inefficient, if not deleterious, for patients with tumors harboring microsatellite instability (MSI) and/or mismatch repair deficiency (dMMR), a tumor phenotype predictive for the efficacy of immune checkpoint inhibitors (ICKi).

Mots clés

Cancer de l’estomac, Gastric cancer, Instabilité des microsatellites, Ipilimumab, Lynch syndrome, Microsatellite instability, Nivolumab, Syndrome de Lynch

Référence

Bull Cancer. 2020 Feb 10;: